Compass Minerals International Valuation
Is CM8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CM8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CM8's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CM8's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CM8?
Key metric: As CM8 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CM8's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | US$1.14b |
| Market Cap | US$614.69m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 8.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CM8's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
SZG Salzgitter | 0.09x | 2.1% | €932.5m |
ACT AlzChem Group | 1.1x | 7.5% | €594.3m |
STO3 Sto SE KGaA | 0.4x | 1.8% | €730.0m |
TKA thyssenkrupp | 0.07x | 0.8% | €2.4b |
CM8 Compass Minerals International | 0.5x | 2.3% | €614.7m |
Price-To-Sales vs Peers: CM8 is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.4x).
Price to Sales Ratio vs Industry
How does CM8's PS Ratio compare vs other companies in the European Metals and Mining Industry?
| 35 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 35 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: CM8 is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Metals and Mining industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is CM8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 0.3x |
Price-To-Sales vs Fair Ratio: CM8 is expensive based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €13.80 | €17.18 +24.5% | 23.9% | €23.61 | €12.27 | n/a | 5 |
| Nov ’25 | €11.00 | €16.03 +45.7% | 24.5% | €22.51 | €11.70 | n/a | 5 |
| Oct ’25 | €10.40 | €16.03 +54.1% | 24.5% | €22.51 | €11.70 | n/a | 5 |
| Sep ’25 | €7.95 | €16.77 +110.9% | 23.3% | €23.29 | €12.11 | n/a | 5 |
| Aug ’25 | €11.90 | €16.77 +40.9% | 23.3% | €23.29 | €12.11 | n/a | 5 |
| Jul ’25 | €9.20 | €16.77 +82.2% | 23.3% | €23.29 | €12.11 | n/a | 5 |
| Jun ’25 | €11.10 | €20.22 +82.1% | 41.1% | €37.04 | €12.04 | n/a | 6 |
| May ’25 | €12.10 | €21.90 +81.0% | 31.4% | €37.39 | €14.02 | n/a | 7 |
| Apr ’25 | €14.60 | €24.25 +66.1% | 23.2% | €36.90 | €18.45 | n/a | 7 |
| Mar ’25 | €20.80 | €27.81 +33.7% | 27.9% | €44.50 | €19.47 | n/a | 7 |
| Feb ’25 | €20.60 | €31.38 +52.3% | 36.3% | €55.14 | €22.06 | n/a | 7 |
| Jan ’25 | €23.40 | €35.69 +52.5% | 41.6% | €68.89 | €22.04 | n/a | 7 |
| Dec ’24 | €22.00 | €35.69 +62.2% | 41.6% | €68.89 | €22.04 | n/a | 7 |
| Nov ’24 | €23.60 | €48.82 +106.9% | 31.7% | €77.84 | €33.23 | €11.00 | 7 |
| Oct ’24 | €25.60 | €48.75 +90.4% | 30.0% | €76.66 | €33.66 | €10.40 | 7 |
| Sep ’24 | €27.40 | €47.96 +75.0% | 30.0% | €75.42 | €33.11 | €7.95 | 7 |
| Aug ’24 | €34.00 | €48.52 +42.7% | 28.1% | €74.66 | €32.78 | €11.90 | 7 |
| Jul ’24 | €30.80 | €49.99 +62.3% | 28.1% | €76.51 | €33.59 | €9.20 | 7 |
| Jun ’24 | €29.40 | €49.99 +70.0% | 28.1% | €76.51 | €33.59 | €11.10 | 7 |
| May ’24 | €29.40 | €50.58 +72.0% | 24.3% | €73.72 | €32.76 | €12.10 | 7 |
| Apr ’24 | €30.20 | €51.26 +69.7% | 24.3% | €74.71 | €33.21 | €14.60 | 7 |
| Mar ’24 | €36.60 | €52.23 +42.7% | 23.7% | €75.55 | €33.58 | €20.80 | 7 |
| Feb ’24 | €42.40 | €58.90 +38.9% | 27.1% | €76.95 | €34.20 | €20.60 | 7 |
| Jan ’24 | €38.40 | €58.90 +53.4% | 27.1% | €76.95 | €34.20 | €23.40 | 7 |
| Dec ’23 | €40.80 | €58.90 +44.4% | 27.1% | €76.95 | €34.20 | €22.00 | 7 |
| Nov ’23 | €40.20 | €61.65 +53.4% | 28.0% | €80.92 | €33.97 | €23.60 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
UBE
JP¥241.7b
Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.
UBE
JP¥15.30
7D
8.5%
1Y
7.7%
Tokuyama
JP¥197.6b
Produces and sells various chemical products in Japan.
TBT
JP¥16.70
7D
5.0%
1Y
16.0%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.27
7D
2.9%
1Y
-8.1%